Healthcare Sep 03, 2020 04:43 PM (GMT+8) · EqualOcean
Beijing CytoNiche Biotech Ltd. closed the Series A fundraising of multi-tens million Chinese yuan. The investment was joined by Phegda Venture Investment Fund, DT Capital Partners and other investors. The company uses the original 3D micro-tissue engineering technology to develop bionic 3D cell products, with a focus on customized lark-scale, automated and high-quality stem cell culture and expansion process. Compared to traditional 2D cell culture, CytoNiche Biotech’s technique can help save 90% space, 90% labor cost, 50% consumables cost and 50% time cost for a broad spectrum of applications, including micro-tissue new drug development and high-throughput candidate selection.

This text is a result of machine translation.